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Application of alginate-polylysine (PLL) capsules for immunoisolation of living cells are suffering from
a varying degree of success and large lab-to-lab variations. In this study we show that these differences in
success rates can be attributed to alginate dependent essential physicochemical changes of the prop-
erties of capsules in vivo that will render the capsules more susceptible to inﬂammatory responses.
Capsule properties were studied before and after implantation by XPS, by immunocytochemistry, and by
measuring zeta potentials. We studied a capsule type which provokes for unknown reasons a strong
inﬂammatory response, i.e. high-guluronic (G) alginate capsules and a capsule type with near identical
physicochemical properties but which evokes a minimal inﬂammatory response, i.e. intermediate-G
alginate capsules. The cause of the difference in response was a decrease in nitrogen content on high-
G capsules due to detachment of PLL in vivo and an increase of the zeta-potential. Our data illustrate
an important overlooked phenomena; the physicochemical properties are not necessarily the properties
after exposure to the in vivomicroenvironment and might induce undesired inﬂammatory responses and
failure of encapsulated cellular grafts.
 2012 Elsevier Ltd. All rights reserved.1. Introduction
Themost commonly applied procedure for immunoprotection is
microencapsulation of tissues in alginate-based capsules as origi-
nally described by Lim and Sun [1]. Alginate, the main component
of the capsule, is composed of chains of guluronic acid (G) and
mannuronic acid (M) and can have varying quantities of these two
acids. The alginate binds polyaminoacids at the surface of the
capsules which provides semi-permeable properties. During recent
years, important advances have been made with this technology.
Human trials have been started and shows temporary but persis-
tent survival of human microencapsulated tissue after allo-
transplantation of encapsulated parathyroid cells [2] and islets of
Langerhans [3e5]. Also, microencapsulation has been shown to
allow for prolonged survival of xenotransplanted islet grafts in both
chemically induced and autoimmune diabetic rodents [6], dogs
[7,8], and monkeys [9]. Although this illustrates the principleand Medical Biology, T2.115,
enter Groningen, Hanzeplein
11045; fax: þ31 50 33619911.
All rights reserved.applicability of the alginate-encapsulation technique, a funda-
mental barrier has to be overcome since graft survival varies
considerably from several days to months [10]. This variation in
success rate is usually attributed to differences in the tissue
responses (i.e. biocompatibility) against the applied capsules.
Many report different causes for the tissue responses against
alginate-based capsules. Purity of the alginate [11e14], the inter-
action of the alginate with the polyamino acid [13,15e18], and the
mechanical stability [12,19] are all considered to be crucial factors
in the responses against the capsules. Also the alginate-type has
been subject of studies focusing on identiﬁcation of factors inﬂu-
encing biocompatibility, but conclusions on which type of alginate
is most adequate can still not be drawn [18]. This is caused by the
fact that in most of these studies alginate-effects are over-
shadowed by variations in experimental design which makes
comparison and sound interpretation difﬁcult if not impossible.
Many studies [18,20] compare alginates with different guluronic
acid content in capsules with a different or poorly documented
stability. Also the applied alginates lack details on purity or have
a documented different degree of purity [12,18,21]. In addition to
capsule properties also other factors such as limitations of the
transplantation site such as the low oxygen tension in the peri-
toneal cavity may contribute to failure and enhancement of host
responses [22].
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microenvironment on physicochemical properties of capsules and
the role of potential changes in the physicochemical properties on
the inﬂammatory responses against the capsules. To this end we
compared the responses and the surface properties of capsules that
provoke a strong inﬂammatory response, i.e. high-G alginate
capsules with that of capsules with a known high degree of
biocompatibility, i.e. intermediate-G alginate capsules. We metic-
ulously selected alginates with a different guluronic acid content
but an identical purity degree to prevent overshadowing responses
associated with contaminations such as endotoxins [12,18,21]. Also
we constructed capsules with a near identical mechanical stability.
Subsequently these capsules were implanted in the peritoneal
cavity of AO-rats to compare the responses and the physical
chemical surface characteristics of these capsules at day 1, 5, and 7
after implantation.
2. Materials and methods
2.1. Graft recipients
Male inbred Albino Oxford (AO/G) rats served as recipients of capsules and were
obtained from the Central Animal Laboratory of Groningen. Their body weights
ranged from 300 to 350 g. NIH guidelines for the care and use of laboratory animals
have been observed.
2.2. Alginates and puriﬁcation procedure
Alginates of different composition were obtained from ISP Alginates Ltd UK.
Intermediate-G (43% G-content) and high-G (greater than 53% G-content). Crude
sodium alginate was dissolved at 4 C in a 1 mM sodium EGTA solution to a 1%
solution for intermediate-G alginate and to a 0.25% solution for high-G alginate
under constant stirring. Subsequently the solutions were ﬁltered over successively,
5.0, 1.2, 0.8, and 0.45 mm ﬁlters (Schleicher & Schüll, Germany). During this ﬁltration
step, all visible aggregates were removed.
Next, the pH of the solution was lowered to 3.5 by addition of 2 N HCL þ 20 mM
NaCl. The solution was kept on ice to prevent hydrolysis of alginate. The next step
was slow lowering of the pH from 3.5 to 1.5 and was associated with gradual
precipitation of alginate as alginic acid [23]. Routinely, the solutions were brought at
a pH of 2.0 and subsequently ﬁltered over a Buchner funnel (pore size 1.5 mm) to
washout non-precipitated contaminants. To extend thewashout of non-precipitated
contaminants, the precipitate was brought in 0.01 N HCL þ 20 mM NaCl, vigorously
shaken, and ﬁltered again over the Buchner funnel. This washing procedure was
performed three times.
Then, proteins were removed by extraction with chloroform/butanol [24]. The
alginic acid was suspended in 100 ml of 0.01 N HClþ 20 mM NaCl and supplemented
with 20 ml chloroform and 5 ml 1-butanol. The mixture was vigorously shaken for
30min and ﬁltered over the Buchner funnel. This chloroform/butanol extractionwas
performed three times. Next, the alginic acid was brought in water and slowly
dissolved by gradually raising the pH to 7.0 by slow addition of 0.5 N NaOHþ 20 mM
NaCl over a period of at least 1 h. The alginate solution obtained was subjected to
a chloroform/butanol extraction to remove those proteins which can only be dis-
solved in chloroform/butanol at neutral pH [24]. The solutionwas vigorously shaken
in a mixture of chloroform (20 ml at each 100 ml alginate solution) and 1-butanol
(5 ml at each 100 ml alginate solution) for 30 min. The mixture was centrifuged
for 3e5 min at 3000 rpm, which induced the formation of a separate chloroform/
butanol phase which was removed by aspiration. The extraction was repeated once.
The last step was precipitation of the alginate with ethanol [25,26]. To each
100 ml of alginate solution we added 200 ml absolute ethanol. After an incubation
period of 10 min all alginate had precipitated. The alginate was ﬁltered over the
Buchner funnel and washed two times with absolute ethanol. Subsequently, the
alginate was washed three times with ethylether. Finally, the alginate was freeze-
dried overnight. In order to include alginates with a similar degree of purity we
only included alginates which after the puriﬁcation had an endotoxin content which
was always <0.006 ng/mg as measured by LAL.
2.3. Encapsulation
Puriﬁed alginates were dissolved at 4 C in Krebs-Ringer-Hepes (KRH) with an
appropriate osmolarity. In order to produce capsules with a similar mechanical
stability we tested intermediate-G capsules and high-G capsules from alginate solu-
tionwith a different concentration. This increases the intracapsular polymer network
and reinforced the stability. For high-G capsules we could not apply solutions higher
than 2% as this produces solutions with a viscosity above 4 cps which is above the
0.2 mm ﬁltration. This latter ﬁltration step is required for sterilization of alginate.In order to qualify for inclusion in this study, the alginate-polylysine solution
should be able to withstand the following challenge for mechanical stability [15,27].
First, we incubated samples of 100 capsules in vitro for 24 h in a hypoosmotic
solution of ultrapure water in a waterbath shaking at a frequency of 60 rounds per
minute (i.e. the so-called explosion assay) [28,29]. The diameter of 10 microcapsules
and the number of broken microcapsules were measured after 24 h. Only capsules
that did not swell more than 10% over a period of 48 h were included.
We tested the mechanical stability of capsules prepared of high-G alginate and
compared it with capsules prepared of solutions with graded loads of intermediate-
G alginates. Only intermediate-G solution with a concentration of 2.8% qualiﬁed.
Before application the solutions were sterilized by 0.2 mm ﬁltration. The alginate
solution was converted into droplets using an air-driven droplet generator as
previously described [30]. Polylysine-alginate encapsulation was performed as
described elsewhere [31]. Brieﬂy, the alginate droplets were transformed to alginate
beads by gelling in a 100 mM CaCl2 (10 mM HEPES, 2 mM KCl) solution for at least
5 min. Subsequently, the Ca-alginate beads were suspended for 1 min in
KrebseRinger Hepes buffer containing 2.5 mmol/l CaCl2. A poly-L-lysine (PLL)
membrane was formed by suspending the alginate beads in 0.1% PLL solution for
10 min (poly-L-lysine-HCl, Mw: 22,000, Sigma). Non-bound PLL was removed by
three successive washings during 3 min with Ca2þ-free KRH containing 135 mM
NaCl. The outer alginate-layer was subsequently applied by 5 min incubation in ten
times diluted alginate solution. The diameters of capsules and beads were measured
with a dissection microscope (Bausch and Lomb BVB-125, and 31e33e66) equipped
with an ocular micrometer with an accuracy of 25 mm. The capsules had a diameter
of 600e700 mm. The same microscope was used for inspection of the capsules prior
to implantation.
2.4. Implantation and explantation of empty capsules
Capsules were injected into the peritoneal cavity with a 16 G cannula via a small
incision (3 mm) in the linea alba. The abdomen was closed with a two-layer suture.
The implanted volume was always 2.0 ml as assessed in a syringe with appropriate
measure. The transplants contained at least 4000 capsules.
For studies to the tissue response in the ﬁrst week we did subject the animals to
a repeated laparatomy. Themicrocapsules were retrieved at day 1, 5, and 7 days after
implantation by peritoneal lavage (at least n¼ 4 per time point). Peritoneal lavage at
day 1 and 5 was performed by infusing 5 ml KRH through a 3 mm midline incision
into the peritoneal cavity and subsequent aspiration of the KRH containing the
capsules.
On day 7 the animals were subjected to laparotomy to inspect the peritoneal
cavity. Microcapsules were either freely ﬂoating and non-adherent, or adherent to
the surface of abdominal organs. First, non-adherent microcapsules were retrieved
by peritoneal lavage, and brought into a syringe with appropriate measures for
quantiﬁcation of the retrieval rate [32]. Subsequently, the microcapsules adherent to
the surface of abdominal organs, were excised and processed for histology.
All surgical procedures were performed under halothane anesthesia.
2.5. X-ray photoelectron spectroscopy (XPS)
For measuring protein adsorption, samples of fresh capsules and capsules
retrieved by lavage at day 1, 5, and 7 after implantation were three times washed
with ultrapure water and gradually lyophilized (Leybold Herecuis, Combitron CMI).
Since the XPS-spectroscope only identiﬁes elements at the surface of the capsules, it
is a prerequisite that the membranes of the capsules are intact and not broken.
Therefore, before applying XPS, we conﬁrmed the integrity of the surfaces and
membranes by scanning electron microscopy [33e35].
Samples of lyophilized beads or capsules with intact capsule membranes were
ﬁxed on a sample holder. The sample holder was inserted into the chamber of an X-
ray photoelectron spectrometer (Surface Science Instruments, S-probe, Mountain
View, CA). An aluminium anode was used for generation of X-rays (10 kV, 22 mA) at
a spot size of 250  1000 mm. During the measurements, the pressure in the spec-
trometer was approximately 107 Pa. First, scans were collected over the binding
energy range of 1e1100 eV at low resolution (150 eV pass energy). Next, we recorded
at high resolution (50 eV pass energy) C1s, N1s, and O1s peaks over a 20 eV binding
energy range. The protein content of the capsule’s surface was expressed as
a percentage of the total C, N, and O content of the membrane. Pure lyophilized PLL
was measured after bringing it on the sample holder in the same fashion as
described above.
Experiments were repeated four times to exclude variations between different
encapsulation sessions.
2.6. Electrophoretic mobility
The zeta potential was measured using the Electro Kinetic Analyzer (EKA, Anton
Paar GmbH, Austria). The EKA operates according to the principles of streaming
potential and includes a powder measuring cell, the electrolyte circuit, and a pair of
Ag/AgCl electrodes. The electrolyte (103 M KCl solution) is forced through the
measuring cell containing the sample. A pressure drop (DP) depending upon the
ﬂow resistance of the sample is detected across themeasuring cell. The circulation of
Table 1
Elemental surface composition of alginate-PLL capsules (n ¼ 4) prepared of
intermediate-G and high-G alginate before implantation.
C (%) N (%) O (%) Others (Na, K, Si) (%)
Day 0
Inter-G 56.2  0.6 5.8  1.2 33.5  1.8 4.5  0.8
High-G 56.0  0.9 5.9  0.5 33.9  0.8 4.2  0.6
Fig. 1. Percentage of freely ﬂoating alginate-PLL capsules prepared of intermediate-G
alginate (closed circles) or high-G alginate (open circles) with cellular overgrowth at
1, 5, and 7 days after implantation in the peritoneal cavity of AO-rats. Values represent
mean  SEM of four experiments.
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resulting potential difference (streaming potential, Up) is detected by electrodes
placed at each end of the cell. During a measurement, DP and Up are recorded.
The zeta potential (z) was calculated using the equation as follows [36]:
z ¼ UP*h*æ
DP*ε*ε0
In this equation h is the dynamic viscosity of the electrolyte solution, æ is its
electrical conductivity, ε is the liquid permittivity, and ε 0 is the permittivity of free
space.
If not otherwise mentioned, the pH of the electrolyte solution was kept at 7.0
since this is the physiological pH to which capsules are exposed in vivo. During the
assessment of the streaming potential, the temperature was kept at 25 C.
2.7. Microscopy
To assess the integrity of capsules before implantation, samples of capsules were
meticulously inspected for the presence of irregularities or broken parts in the
capsule membranes by using a dissection microscope.
To detect physical imperfections and to assess the composition and degree of
overgrowth after implantation, samples of adherent capsules recovered by excision
and samples of non-adherent capsules were ﬁxed in pre-cooled 2% para-
formaldehyde, buffered with 0.05 M phosphate in saline (Ph 7.4), and processed for
glycol methacrylate (GMA) embedding [37]. Sections were prepared at 2 mm and
stained with RomanovskyeGiemsa stain and applied for detecting imperfections in
the capsule membrane and for quantifying the composition of the overgrowth and
determining the number of capsules with and without overgrowth. Different cell-
types in the overgrowth were assessed by identifying cells in the capsular over-
growth with the morphological characteristics of monocytes/macrophages,
lymphocytes, granulocytes, ﬁbroblasts, basophiles, erythrocytes, and multinucle-
ated giant cells. To conﬁrm the adequacy of this approach, portions of adherent and
non-adherent capsules were frozen in precooled iso-propane, sectioned at 5 mm, and
processed for immuno-histohemical staining and quantiﬁcation of the different cell
types as previously described [38]. The monoclonal antibodies used were: ED1 and
ED2 against monocytes and macrophages [39], HIS-40 against IgM bearing B-
lymphocytes [40], and R73 against CD3þ bearing T-lymphocytes [41]. In control
sections we used PBS instead of the ﬁrst stage monoclonal antibody. Quantiﬁcation
of these cells types after immunocytochemistry were compared with the assess-
ments on the basis of morphological markers and always gave similar results.
The degree of capsular overgrowth was quantiﬁed by expressing the number of
recovered capsules with overgrowth as the percentage of the total number of
recovered capsules for each individual animal.
2.8. Statistical analysis
Results are expressed as mean  SEM. Statistical comparisons were made with
the Mann Whitney U test. A P-value <0.05 was considered statistically signiﬁcant.
3. Results
A major pitfall in the studies comparing alginates with different
composition has been the application of capsules that not only vary
in the type of alginate but also have a different purity or mechanical
stability [11e18]. This has interfered with sound interpretation of
the effect of alginate types due to overshadowing effects of purity
issues and responses to broken capsules. Therefore, in this studywe
selected alginates with an endotoxin content <0.006 ng/mg.
Endotoxin content is a crucial factor in provoking purity-related
inﬂammatory responses [18]. A concentration of <0.006 ng/mg is
considered to be far below the level that could induce an inﬂam-
matory response [4,18] and below the endotoxin content of
commercially available alginates. Also, we constructed capsules
with an identical mechanical stability.
3.1. Surface properties before implantation
Before implantation we compared the surface properties of the
constructed capsules by applying XPS. In previous studies we
showed that especially variations in poly-L-lysine content, i.e. N-
content, can be hold responsible for inﬂammatory responses
[34,42]. In the present studywe therefore engineered capsules with
a similar N-content (Table 1). Also we measured the zeta-potential
of the capsules as a measure for the amount of unbound poly-lysineon the capsules surface. Free positive charges on high-G capsules
are considered to be responsible for inﬂammatory responses.
Before implantation, the applied high-capsule grafts had a zeta-
potential of 3.6  0.2 mV which value was similar if not iden-
tical to the zeta-potential of intermediate-G capsule grafts
(3.5  0.2 mV).
3.2. Tissue response in the immediate post-transplant period
In spite of the similarities in purity, mechanical stability, and the
physicochemical properties of the capsules we observed different
responses against the capsules after implantation in the peritoneal
cavity of AO-rats. The majority of capsules prepared of
intermediate-G alginate capsules were freely ﬂoating in the peri-
toneal cavity while the majority of the high-G alginates capsules
were found to be adherent to the surface of the abdominal organs
as illustrated by a high retrieval rate of the intermediate-G alginate
capsules and a low retrieval rate of the high-G alginate capsules.
With intermediate-G alginate, we washed out 20e40% of the
capsule graft from the rat peritoneal cavity on day 1, 5, and 7 after
implantation while it was only 10e30% with high-G alginate. After
the three lavages, the total retrieval rate of the capsules was 92 8%
for intermediate-G alginate which was signiﬁcantly higher than the
45  6% for high-G alginate (P < 0.01). The majority of the capsules
prepared of high-G alginatewas found to be adherent to the surface
of abdominal organs. These adherent capsules were all overgrown.
The tissue responses against intermediate-G alginate capsules
were always less severe than against high-G alginate capsules. The
percentage of capsules with cellular overgrowth with
intermediate-G alginate increased during prolonged stay in the
peritoneal cavity from 0.6  0.4% on day 1 to 2.8  1.4% on day 7
while with high-G alginate it was 1.5  0.7% on day 1e85.3  9.4%
on day 7 (Fig. 1).
3.3. Differences in the composition of the cellular overgrowth
With both types of alginate we found the overgrowth on
capsules recovered by peritoneal lavage to be composed of mono-
cytes/macrophages, granulocytes, ﬁbroblasts, erythrocytes,
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done in GMA-embedded sections and it was conﬁrmed by applying
immunocytochemistry on frozen sections. As in previous studies
with empty capsules [43], we found no elements of the speciﬁc
immune system such as B- or T-lymphocytes.
During the tissue response against microcapsules we observed
an immediate inﬂux and adherence to the capsules of monocytes,
macrophages, granulocytes, and some basophils. These inﬂamma-
tory cells gradually disappear from the capsule surface during
prolonged stay in the peritoneal cavity (Fig. 2). When the inﬂam-
matory cells disappear from the capsule surface, we observed
a ﬁbroproliferative response characterized by an inﬂux of ﬁbro-
blasts and the development of ﬁbroconnective tissue around the
capsules.
Although the same cell-types were involved in the tissue
response against intermediate-G and high-G alginate, we found at
day 5 after implantation moremonocytes/macrophages (P< 0.001)
and less ﬁbroblasts (P < 0.05) on the overgrown intermediate-G
capsules than on the overgrown high-G capsules. This illustrates
a faster initiation of the ﬁbroproliferative response against high-G
capsules than against intermediate-G capsules.
With both intermediate-G and high-G alginate we found some
erythrocytes, multinucleated giant cells but these were present in
too low numbers to allow for reliable quantiﬁcation. Erythrocytes
were found on capsules at day 1 but not on later days suggesting
that the erythrocytes have been introduced during or after trauma
associated with the surgical implantation of the capsules. Multi-
nucleated giant cells were absent in slices of capsules retrieved at
day 1 and present in low numbers in slices of capsules retrieved at
day 5 and 7. Multinucleated giant cells weremainly observed in and
around capsules containing localized defects suggesting that these
cells are involved in breakdown of imperfect capsules.Fig. 2. Frequency of granulocytes (top left), macrophages (top right), ﬁbroblasts (bottom l
prepared of intermediate-G alginate (closed circles) or high-G alginate (open circles) on da3.4. Tissue response at week 2, 4, and 8 weeks after implantation
It has been assumed that the reaction against capsules is
complete within seven days after implantation [35,44,45]. This
assumption is based on quantiﬁcation of the number of capsules
that is affected by cellular overgrowth and not on analyses of the
composition of the overgrowth. Therefore, we repeated the
implantation studies with intermediate-G alginate and high-G
alginate and retrieved the capsules at 2 weeks (n ¼ 4), 4 weeks
(n ¼ 5), and 8 (n ¼ 4) weeks after implantation for analyses of the
number of overgrown capsules and composition of the inﬁltrate. In
these experiments, the animals were not subjected to repeated
peritoneal lavages but sacriﬁced for peritoneal lavage and excision
of the capsules from the abdominal organs.
With intermediate-G alginate, we washed out more than 85% of
the capsule graft from the rat peritoneal cavity on week 2, 4, and 8
after implantation. The retrieval rate was much lower with high-G
alginate. At 2 weeks after implantation we retrieved less than 20%
of the initially implanted capsules. This further decreased to
a retrieval rate of zero at 4 and 8 weeks after implantation. At these
time points all capsules prepared of high-G alginate were found to
be adherent and integrated into the abdominal organs, overgrown,
and covered by ﬁbroproliferative tissue (Table 2).
The percentage of overgrown capsules in grafts composed of
intermediate-G alginate was 4.2  2.1% at two weeks after
implantation and not statistically signiﬁcantly different from the
portion overgrown capsules at day 7 after implantation. However,
at 4 weeks and 8 weeks post-implant we found respectively,
7.8  1.1% and 7.2  0.8% of the retrieved capsules to be affected by
cellular overgrowth which were statistically signiﬁcantly higher
percentages than that found at two weeks and 7 days after
implantation (P always < 0.05).eft), and basophils (bottom right) in the cellular overgrowth on alginate-PLL capsules
y 1, 5, and 7 after implantation. Values represent mean  SEM of four experiments.
Table 2
Composition of cellular overgrowth on alginate-PLL capsules at 2, 4, and 8 weeks after implantation in the peritoneal cavity of AO-rats.
Weeks after implantation n Intermediate-G alginate High-G alginate
Monocytes/macrophage Fibroblasts Monocytes/macrophagess Fibroblasts
2 4 40.4  8.3 59.2  6.8 18.8  2.6 81.1  8.2
4 5 22.5  4.1 77.1  10.4 e 100%
8 4 2.2  0.8 97.6  8.6 e 100%
P. de Vos et al. / Biomaterials 33 (2012) 5552e55595556The composition of the tissue response was also subject to
change after the ﬁrst 7 days of transplantation. As of week two, we
found predominantly monocytes, macrophages, ﬁbroblasts, and
occasionally multinucleated giant cells. The granulocytes and
basophils we observed in the ﬁrst week after implantation had
disappeared from the graft. Monocytes/macrophages will stay
somewhat longer in the graft but also disappear in due time. The
rate of disappearance is alginate-type dependent. With
intermediate-G alginate we found that at four weeks postimplant
a substantial portion of the cells to be composed of monocytes/
macrophages while with high-G alginate virtually all monocytes/
macrophages had been deleted from the grafts. It took till week 8
with intermediate-G alginate before virtually all monocytes/
macrophages had disappeared from the graft.
3.5. Surface properties after implantation
From the foregoing follows that the differences in the responses
against the microcapsules prepared of intermediate-G and high-G
alginate already occurs in the ﬁrst days after implantation. As we
implanted capsules with identical physico-chemical and mechan-
ical properties we questioned whether the capsules might undergo
changes in vivo that might be hold responsible for the differences in
responses. As we found in a recent in vitro study [46] that the
properties of the capsules surface may change after exposure to
human peritoneal ﬂuid we questioned whether there might be
a difference in properties of the intermediate and high G capsules
after implantation. To this end we implanted in a separate series of
experiments capsules in the peritoneal cavity of rats which were
retrieved by peritoneal lavage at 1, 3, and 7 days after implantation.
First we compared the protein adsorption at the capsule surface
after implantation. This was done by XPS (Table 3). After implan-
tation of intermediate-G capsules, the nitrogen signal gradually
increases from 5.8% but to 8.6% at day 7 (P < 0.05) as the conse-
quence of protein release in the vicinity of capsules and adsorp-
tion of those proteins by the capsule’s surface. With high-G
capsules we observed a somewhat different proﬁle. Initially we
observed a statistical signiﬁcant decrease (P < 0.05) of the N-signal
from 6.0  0.5% on fresh capsule to 5.5  0.3% at day 1 after
implantation. Thereafter we found an increase from 5.5  0.3% onTable 3
Elemental surface composition of alginate-PLL capsules (n ¼ 4).
C (%) N (%) O (%) Others (Na, K, Si) (%)
Day 0
Inter-G 57.2  0.8 5.8  0.6 34.3  2.1 2.7  0.8
High-G 55.3  0.7 6.0  0.5 33.9  0.8 4.8  0.6
Day 1
Inter-G 57.8  3.6 5.8  1.0 30.0  3.9 6.4  1.0
High-G 56.1  1.0 5.5  0.3 34.2  1.6 4.2  0.6
Day 5
Inter-G 58.9  1.7 7.2  0.9 30.1  1.2 3.8  0.4
High-G 64.5  4.1 7.4  0.8 23.2  2.3 4.9  0.8
Day 7
Inter-G 61.6  2.6 8.6  0.8 26.3  2.7 3.5  0.5
High-G 62.3  2.4 7.5  0.6 27.1  2.9 3.1  0.3day 1 to 7.5  0.6 at day 7 after implantation. This decrease in N
signal reﬂects a loss of PLL at the surface of high G capsules and
exposure of positive charges. Free positive charges on high-G
capsules are considered to be responsible for inﬂammatory
responses and are considered to be causative for inﬂammatory
responses to alginate-PLL capsules [34,47]. To measure possible
positive charges on capsules we quantiﬁed the zeta-potential of
implanted capsules at day 1 after implantation. Although the zeta-
potential of intermediate and high-G capsules was equal at the day
of implantation, we found that the zeta potential of high-G capsules
increased to0.5 0.7 mV at day one after implantation (P< 0.01).
This was not observed with intermediate-G capsules.4. Discussion
In the present study we show that in spite of similar mechanical
and physicochemical surface properties high-alginates capsules
provoke a stronger inﬂammatory response than capsules prepared
of intermediate-G alginate. We show that this is caused by unde-
sired changes on the surface of the high-G capsules with an
increase of the zeta-potential as a consequence. This increase
reﬂects an elevation of the number of positive charges at the
surface. This is a well-known factor in cell adhesion and inﬂam-
matory responses against microcapsules [36,47]. On the basis of our
results we propose the following mechanism (Fig. 3). The high-G
and intermediate-G capsules have similar physicochemical prop-
erties before implantation. This changes rapidly after implantation.
After implantation, a non-speciﬁc immune response is activated
with inﬂux of cells and pH changes in the implantation site as
a consequence [38,48e54]. This together with adsorption of
proteins from the peritoneal ﬂuid [46] may result in structural
surface changes. Alginate-PLL capsules prepared of intermediate-G
alginate seem to be resistant to the changing microenvironment in
the implantation site. This however is different with the capsules
prepared of high-G alginate which loose, as shown in the present
study, some poly-L-lysine immediately after implantation and
contains at day 1 after implantation many positive charges from
poly-L-lysine molecules that are not bound to alginate at the
surface. This results in cellular adhesion and ﬁbrosis of the high-G
microcapsules.
It might be suggested that different results may be obtained if
other polycations than poly-L-lysine would have been applied.
However, we selected poly-L-lysine for a reason. In a previous study
[15] we investigated the effect of poly-L-lysine (PLL), poly-D-lysine
(PDL) and poly-L-ornithine (PLO) and found that only PLL was
associatedwithminimal inﬂammatory responses. PLL requires G-M
blocks to interact with the alginate matrix [55]. It is unknownwhat
ligand is required for other polycations such as PDL and PLO for
optimal interaction with alginate matrices.
Our study illustrates an important and overlooked item in
encapsulation research, i.e. the physicochemical properties in vitro
are not necessarily the properties after exposure to the in vivo
microenvironment. Upon exposure to body ﬂuids microcapsules
will adsorb bioactive components which will change the properties
of the capsule surface and the responses against the capsules
Fig. 3. Fresh alginate-PLL capsules can have similar physicochemical properties. This will change after implantation in an alginate type dependent way. After implantation, a non-
speciﬁc immune response occurs with inﬂux of cells and pH changes in the implantation site as a consequence. This change in the microenvironment of the capsules results on
high-G alginate PLL capsules in structural changes such as an elevation of the positive charges at the surface with cell adhesion and inﬂammatory responses against the high-G
microcapsules as a consequence. Intermediate-G alginate PLL capsules are not sensitive for the changes in the microenvironment and remain free from cellular adhesion.
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in body ﬂuids changes the properties and charge density of
capsules making capsules more susceptible for adsorption of body
proteins and inﬂammatory responses [36]. We now conﬁrm that
this also occurs in vivowith alginate-poly-L-lysine capsule prepared
of high-G alginate while capsules of intermediate-G alginate can
resist the in vivo microenvironment. Our data suggest that for
predicting biocompatibility of alginate-based capsules we should
not only focus on the properties of the freshly prepared capsules
but also on the properties of the capsule surface after exposure to
body ﬂuids. Our recently published system in which capsules are
ﬁrst incubated to peritoneal ﬂuid and subsequently exposed to
human peripheral blood mononuclear cells to quantify inﬂamma-
tory responses may serve as a fast in vitro assay to predict proin-
ﬂammatory structural surface changes on alginate-based capsules
after exposure to body ﬂuids [46].
Our study was not only performed to identify the cause for the
difference in responses against capsules prepared of different types
of alginate but also to gain more insight in the composition of the
inﬂammatory responses against alginate-based microcapsules. At
present many groups focus on the design of means to reduce
inﬂammatory responses in the immediate period post-transplant
as this is associated with a signiﬁcant loss of tissue in the capsules
[56]. In order to design adequate intervention strategies we require
more detailed insight in the cellular composition of the responses,
its dynamics and whether it is alginate dependent. We show in the
present study that this inﬂammatory response is a dynamic rather
than a static process involving many different cell types in a time
dependent fashion. We show that in the ﬁrst week after implan-
tation the capsules attract many cell types such as monocytes/
macrophages, granulocytes, ﬁbroblasts, erythrocytes, multinucle-
ated giant cells, and basophiles which population of cells is reduced
to monocytes/macrophages and ﬁbroblasts in the second week.
After the second week we observe a gradual disappearance of the
monocytes/macrophages which were substituted by ﬁbroblasts.
Although, we found with intermediate-G and high-G alginate no
difference in the type of cells involved the tissue response, wefound an earlier decrease in number of inﬂammatory cells and
a faster ﬁbroproliferative response with high-G than with
intermediate-G capsules.
Inﬂammatory cells such as monocytes and macrophages have
been shown to produce cytotoxic components with deleterious
effects for enveloped tissue such as pancreatic islets [57e60]. Loses
of up to 60% of the insulin producing islet grafts has been reported
[44,56]. An inﬂammatory response cannot be avoided since it starts
already with the mandatory surgery to implant the capsules and
since it cannot be avoided that some capsules contain imperfection
[21,35,42,56] and provoke a response. Therefore, the current
strategy of many research groups is to apply anti-inﬂammatory
drugs to inhibit the activation of monocytes and macrophages in
the vicinity of the capsules [44,45]. In most cases these drugs are
applied in the immediate posttransplant period up to two weeks.
Our data show however that activated macrophages and mono-
cytes can be found up to 8 weeks after implantation. This was even
found on grafts that elicit not more than a minimal response to not
more than 7% of the capsules. We therefore conclude that it might
be advisable for prevention of loss of the enveloped tissue to apply
anti-inﬂammatory drugs for longer periods of up to 8 weeks after
implantation.
The high-G capsules membranes have a lower protein content at
day 1 after implantation than before implantation was an unex-
pected observation. This indicates loss of PLL from the capsule
membrane immediately after implantation. It may be suggested
that it corroborates a previous suggestion that high-G alginate
takes up excessive amounts of PLL during the coating procedure
with the polyamino-acid since high-G only has limited numbers of
binding sites for PLL [12,55]. In our experimental set up however
we washed the capsules excessively and did zeta-potential
measurements before implantation to conﬁrm that the capsules
did not contain any unbound poly-L-lysine. Rather our data
corroborate our recent observations that high-G alginate-PLL
complexes are less stable and more susceptible for structural
changes in body ﬂuid than intermediate-G-PLL complexes [36,46].
This could be explained by the fact that intermediate-G alginate
P. de Vos et al. / Biomaterials 33 (2012) 5552e55595558contains more G-M block polymer than high-G alginates. These G-
M blocks are responsible for PLL binding and the formation of stable
a-helix, antiparallel b-sheet and random coil conformation [55].
Our data therefore suggest to avoid the application of high-G
alginates for the preparation of alginate-PLL capsules.
During the past decade many procedures to fabricate alginate-
based capsules have been described. Unfortunately, most of these
procedures lack an adequate documentation of the characterization
of the microcapsules [18]. As a result many procedures show an
extreme lab-to-lab variation and cannot be adequately reproduced.
Our present results illustrate that adequate documentation of the
polymers and standarization of testing procedures can no longer be
neglected as we show that a minor difference in G-content of the
applied alginate of not more than 10% has a profound effect on the
responses against the capsules. In most studies the alginate type is
poorly or not documented at all [18]. Our data suggest that this is an
important factors contributing to the extreme lab-to-lab variations
of the technology [18,21].5. Conclusion
We show that alginate-based capsules may undergo undesired
physicochemical changes in vivo. These changes are dependent on
the type of alginate applied. As a consequence of these in vivo
changes, high-G capsules provoke an inﬂammatory responsewhich
is different in composition, in numbers of inﬂammatory cells, and
in duration when compared to intermediate-G capsules. The
detachment of PLL in vivo and an increase in positive charges on the
capsule surface should be hold responsible for these strong
responses against high-G capsules. We feel wemay conclude on the
basis of our results that our study illustrate an important over-
looked issue; the physicochemical properties in vitro are not
necessarily the properties after exposure to the in vivo microenvi-
ronment. The changes in vivo should gain more attention in future
engineering efforts.References
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